October 07, 2020
Although the minimum eligibility for psoriasis treatment is typically a Psoriasis Area and Severity Index (PASI) score of 10 or 12, which is considered moderate psoriasis, patients with lower scores can still have major quality of life impairment, according to a study published online in the Journal of The European Academy of Dermatology and Venereology.
Researchers were interested in seeing whether common clinical thresholds for defining moderate psoriasis—PASI score of 10 to 12 and percent body surface area (BSA) involvement of 10—were in line with patient-reported Dermatology Life Quality Index (DLQI) data. To do so, they conducted a systematic review of randomized controlled trials and considered correlations between provider measures of psoriasis severity and patient feedback on the DLQI.
Among patient groups with DLQI scores above 10, which point to a high quality-of-life impact, the study found an average weighted BSA of just 7.6 and an average weighted DLQI of 11. Such patients had an average weighted PASI of 8.7 and an average weighted DLQI of 10.9.
“In general, the objective measures of BSA and PASI alone, when excluding DLQI, may not fully capture the impact of disease severity,” researchers advised.
Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact [published online ahead of print, 2020 Sep 25]. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16966. doi:10.1111/jdv.16966